



***NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO***

## **Comunicato Stampa**

### **ESERCIZIO DELL'OPZIONE GREENSHOE**

### **COMUNICAZIONE FINALE RELATIVA ALL'ATTIVITA' DI STABILIZZAZIONE**

**Roma, 6 dicembre 2018** – Garofalo Health Care S.p.A. (la “Società” o “GHC”) comunica che in data 5 dicembre 2018 Equita SIM S.p.A., quale agente per la stabilizzazione sulle azioni ordinarie GHC, ha esercitato, per conto di Credit Suisse e della stessa Equita SIM S.p.A. - quali *Joint Global Coordinator* -, integralmente la c.d. opzione *greenshoe* per n. 2.000.000 azioni ordinarie della Società. Con l'esercizio dell'opzione *greenshoe* termina con effetto immediato il periodo di stabilizzazione.

Si ricorda che il prezzo di acquisto delle azioni oggetto dell'opzione *greenshoe* è di Euro 3,34 per azione – corrispondente al prezzo di offerta stabilito nell'ambito del collocamento istituzionale – per un controvalore complessivo pari a Euro 6.680.000,00, al lordo delle commissioni riconosciute nell'ambito del collocamento istituzionale.

Il regolamento dell'opzione *greenshoe* sarà in data e per valuta 7 dicembre 2018 e, in pari data, le azioni rivenienti dall'esercizio dell'opzione *greenshoe* saranno consegnate all'azionista Maria Laura Garofalo a chiusura dell'opzione di *over-allotment* dalla stessa concessa ai *Joint Global Coordinator*.

Incluse le azioni oggetto dell'opzione *greenshoe*, il collocamento istituzionale ha riguardato pertanto n. 22.000.000 azioni ordinarie GHC, pari a circa il 26,8% del capitale sociale.

Inoltre, sempre sulla base di quanto comunicato da Equita SIM S.p.A., quale agente per la stabilizzazione sulle azioni ordinarie GHC e anche per conto della stessa, GHC rende noto che durante il periodo di stabilizzazione, dalla data di inizio delle negoziazioni delle azioni ordinarie GHC sul Mercato Telematico Azionario organizzato e gestito da Borsa Italiana S.p.A. (9 novembre 2018) fino alla data odierna, non è stata effettuata alcuna operazione di stabilizzazione.

Il presente comunicato è diffuso anche per conto di Equita SIM S.p.A. ai sensi dell'art. 8, lettera f), e dell'art. 6, comma 3, del Regolamento Delegato (UE) 2016/1052.

\* \* \*

Credit Suisse e Equita SIM S.p.A. hanno agito in qualità di *Joint Global Coordinator* e *Joint Bookrunner*. Equita SIM S.p.A. agisce altresì in qualità di Sponsor. Lazard agisce in qualità di *advisor finanziario* della Società.

Gianni, Origoni, Grippo, Cappelli & Partners, Shearman & Sterling forniscono l'assistenza legale a favore della Società, rispettivamente, per gli aspetti di diritto italiano e per quelli di diritto americano e inglese, mentre Linklaters fornisce l'assistenza legale a favore dei *Joint Global Coordinator* e dello Sponsor. Studio Associato Tributario Bagnera & Associati fornisce assistenza fiscale alla Società. EY è la società di revisione.



**PER ULTERIORI INFORMAZIONI:**

Garofalo Health Care S.p.A.

Mimmo Nesi - Investor Relator

Tel. +39 06 68489231 - [ir@garofalohealthcare.com](mailto:ir@garofalohealthcare.com)

Sito internet: [www.garofalohealthcare.com](http://www.garofalohealthcare.com)

**Ufficio Stampa**

Community – Communication Advisers

Auro Palomba – Marco Rubino – Giuliana Pampani – Tel.+390289404231 [marco@communitygroup.it](mailto:marco@communitygroup.it)

\* \* \*

**Il Gruppo GHC**

Il Gruppo GHC, quotato alla Borsa di Milano, è tra i principali operatori del settore della sanità privata accreditata in Italia ed opera attraverso diciotto strutture sanitarie d'eccellenza, situate tra le più virtuose regioni italiane, offrendo un'ampia gamma di servizi che coprono tutti i comparti della sanità grazie ad una diversificazione delle specialità erogate, all'utilizzo di tecnologie all'avanguardia ed al personale altamente qualificato. In particolare, il Gruppo opera in sei Regioni del Nord e del Centro Italia (Piemonte, Veneto, Emilia Romagna, Liguria, Toscana e Lazio), in cui è presente nel settore ospedaliero, attraverso i comparti dei ricoveri acuti, delle lungodegenze e delle riabilitazioni post-acuzie e delle prestazioni ambulatoriali (il "Settore Ospedaliero") e nel settore territoriale e socio-assistenziale, attraverso i comparti dei ricoveri in regime residenziale e delle prestazioni ambulatoriali distrettuali (il "Settore Territoriale e Socio-Assistenziale").

Al 31 dicembre 2017 il Gruppo GHC ha registrato un totale ricavi e altri proventi pari a Euro 136,7 milioni e un Operating EBITDA pari a Euro 24,9 milioni (totale ricavi e altri proventi pro-forma pari a Euro 152,2 milioni, Operating EBITDA pro-forma pari a Euro 27,4 milioni). Per i nove mesi chiusi al 30 settembre 2018 il Gruppo GHC ha registrato un totale ricavi e altri proventi pari a Euro 115,3 milioni (in crescita del +17,2% rispetto ai primi nove mesi del 2017) e un Operating EBITDA pari a Euro 22,2 milioni (in crescita del +25,4% rispetto allo stesso periodo dello scorso anno).

\* \* \*



These materials are not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Canada, Australia and Japan (or in any other jurisdiction where it is unlawful to do so). This communication does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States, Canada, Australia and Japan or in any other jurisdiction where it is unlawful to do so. This document is being distributed only by or with the approval of an authorised person or to (i) persons who are outside the United Kingdom (ii) persons in the United Kingdom who have professional experience in matters related to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amendend) of the United Kingdom (the "Order") (iii) persons who fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Order, and (iv) any other persons to whom this document may otherwise lawfully be directed (all such persons together being referred to as "relevant persons"). The investments to which this document relates are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such investments will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This document is an advertisement and is not a prospectus for the purposes of the Directive 2003/71/EC of the European Parliament at the Council of November 4th, 2003, as amended, in particular by Directive 2010/73/UE (together, the "Prospectus Directive"). A prospectus prepared pursuant to the Prospectus Directive will be published exclusively for the purposes of the listing of the Company's shares on the MTA.. An international offering circular will be made available in connection with the Offering described below. Investors should not subscribe for any securities referred to in this document except on the basis of information contained or the international offering circular which include detailed information regarding the Company and the risks involved in investing in the securities. In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented by the relevant Member State) and includes any relevant implementing measure in the relevant Member State. In Canada the Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the Shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

This announcement contains inside information within the meaning of Article 7(1) of Regulation (EU) no. 596/2014. Upon publication of this announcement, this inside information is now considered to be in the public domain, and any persons previously in possession of such inside information will no longer be considered to be in possession of inside information following publication of this announcement.

The distribution of this press release is not made, and has not been approved, by an "authorized person" within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Article 19(5) ("investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended), (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (iv) are persons to whom this press release may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.



The distribution of this document in certain countries may constitute a breach of applicable law. The information contained in this document does not constitute an offer of securities for sale in Canada, Australia or Japan. This press release may not be published, forwarded or distributed, directly or indirectly, in Canada, Australia or Japan.

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares of the Company (the "**Shares**") have been subject to a product approval process, which has determined that such Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II to such target market (the "**Target Market Assessment**"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Shares may decline and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offering. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Global Coordinators and Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.

No representation or warranty, express or implied, is made by Credit Suisse and Equita SIM S.p.A. (the "**Managers**"), or any of their respective affiliates, directors, officers, employees, advisers or agents as to the accuracy or completeness or verification of the information contained in this announcement, and nothing contained herein is, or shall be relied upon as, a promise or representation by the Managers in this respect, whether as to the past or future.

None of the Managers assumes any responsibility for its accuracy, completeness or verification and accordingly the Managers disclaim, to the fullest extent permitted by applicable law, any and all liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or any such statement.

The Managers are each acting exclusively for the Company in the transaction referred to in this announcement and for no-one else in connection with any transaction mentioned in this announcement and will not regard any other person (whether or not a recipient of this announcement) as a client in relation to any such transaction and will not be responsible to any other person for providing the protections afforded to their respective clients, or for advising any such person on the contents of this announcement or in connection with any transaction referred to in this announcement. The contents of this announcement have not been verified by the Managers.